CXCL8 and lung cancer: This association was confirmed in the subgroup of lung cancer patients for IL-8 level at the RTduring (HR: 1.014, 95% CI: 1.001–1.027, p = 0.038), RTend (HR: 1.018, 95% CI: 1.003–1.018, p = 0.017) and FU1 (HR: 1.007, 95% CI: 1.002–1.012, p = 0.008) time points.